Thaci, D., Gordon , K. , Gooderham, M., Strober , B., Korman, N., Banerjee, S., Banerjee, S., Colston, E., Kim, J., Throup, J. and Morita, A. 2021. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s37. DOI:https://doi.org/10.25251/skin.5.supp.37.